Proton pump inhibitor to the hepatic cirrhosis patients with hematemesis melena: A retrospective study

Background: The Proton Pump Inhibitor (PPI) can be given as supportive therapy in hepatic cirrhosis patients with hematemesis melena during treatment at the hospital. However, the use of proton pump inhibitor therapy as a supportive therapy for hepatic cirrhosis patients with hematemesis melena has not been widely used in hospitals. Objective: This study aims to determine the pattern of use of proton pump inhibitor (PPI) in patients with hepatic cirrhosis with hematemesis melena in the hospital. Method: This study is a retrospective descriptive non-experimental. Sampling was obtained from secondary data medical records of patients that diagnosed hepatic cirrhosis with hematemesis melena. The variables observed were patients with hepatic cirrhosis with hematemesis melena such as age, gender, type of drug, dose, route of use, the frequency of administration, duration of drug administration, and clinical symptoms. Results: The most widely used PPI was omeprazole with intravenous route with a dose of 1x40mg and 2x40mg (61.54%), oral omeprazole route with a dose of 2x20mg (7.69%), intravenous route pantoprazole with a dose of 1x40mg and 2x40mg (5.13%), and intravenous lansoprazole route with a dose of 1x30mg and 2x30mg (48.72%). Conclusion: The pattern of using proton pump inhibitor therapy in hepatic cirrhosis patients with hematemesis melena is different in each patient.